Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Blinded Endpoint Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke

NCT07301372 is registered in ClinicalTrials.gov with The Affiliated Hospital of Xuzhou Medical University as lead sponsor.

NCT NCT07301372
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07301372 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Blinded Endpoint Evaluation Study of Early Administration of Evolocumab After Thrombolysis in Patients With Atherosclerotic Acute Ischemic Stroke
Lead sponsor
The Affiliated Hospital of Xuzhou Medical University
Phase
Phase 2
Overall status
Completed
Start date
October 30, 2025
Completion date
June 1, 2026
Enrollment
132 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute stroke